Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose- limiting

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1965-1973

  Gordon, A N ^a   Stringer, C A ^a   Matthews, C M ^a   Willis, D L ^a   Nemunaitis, J ^a  

^a Physician Reliance Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CISPLATIN; CORTICOSTEROID; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030913598     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1965     Document Type: Article

References (25)

1. Cancer Facts & Figures-1995. New York, NY, American Cancer Society, 1995
2. Heinz AP, Hacker NF, Lagasse LD: Epidemiology and etiology of ovarian cancer: A review. Obstet Gynecol 66:127-135, 1974
3. Cohen CJ, Goldberg JD, Holland JF, et al: Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second look operation). Am J Obstet Gynecol 145:955-965, 1983
4. Young RC, von Hoff DD, Gormley P, et al: Cis-dicloro-diammine-platinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63:1539-1544, 1979
5. Hoskins PJ, O'Reilly SE, Swenerton KD, et al: Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multi modality therapy. J Clin Oncol 10:1561-1568, 1992
6. Venesmaa P: Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 84:8-11, 1994
7. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
8. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
9. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
10. McGuire WP, Hoskins WF, Brady MF, et al: An assessment of dose intense therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
11. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
12. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
13. Eisenhauer EA, Ten Bokkel H, Swenerton K, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
14. Rowinsky EK, Chaudhry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
15. Omura GF, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at 2 dose levels and filgrastim at 2 dose in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. Proc Am Soc Clin Oncol 15:755, 1996 (abstr)
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
17. National Institutes of Health-Consensus Development Conference Statement. Gynecol Oncol 55:S4-S14, 1994
18. Shiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with and without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
19. Connelly E, Markman M, Kennedy A, et al: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity. Gynecol Oncol 62:166-168, 1996
20. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
21. Sewaldt VL, Greer BE, Cain JM, et al: Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II trial. Am J Obstet Gynecol 170:1666-1671, 1994
22. Rose P, Piver MS: Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57:270-272, 1995
23. Hruban RH, Yardley JH, Donehower RC, et al: Taxol toxicity-Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944-1950, 1989
24. Bookman MA, McGuire WP, Kilpatrick D, et al: Phase I Gynecologic Oncology Group (GOG) study of 3-H and 24-H paclitaxel with carboplatinum as initial therapy in advanced epithelial ovarian cancer (OvCa). Proc Am Soc Clin Oncol 14:271, 1995 (abstr)
25. Rosenfeld CS, Nemunaitis J: The role of granulocyte-macrophage colony-stimulating factor-stimulated progenitor cells in oncology. Semin Hematol 29:19-26, 1992 (suppl 3)